BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence Of Decompensated Liver Disease

Links shared publicly online about this topic.

  • 469
    total visits

BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence Of Decompensated Liver Disease

medicalnewstoday.com —

Bristol-Myers Squibb (NYSE:BMY) announced that BARACLUDE® (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients wi

View full resource at medicalnewstoday.com

Tags: Liver, Liver Condition, Hepatitis B Medication, Disease and Condition, Baraclude, Bristol-Myers Squibb, disease

  • Share

Most Recently Shared on March 2, 2011 at 9:05 am By:

mnt_drugapprov MNT Drug Approvals

BARACLUDE(R) (Entecavir) Approved By The European Commission For The Treatment Of CHB In Adult Patients With Evidence ... http://mnt.to/3RKX

1 year ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Liver Disease MNT Liver Disease

Advertisement